查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1182201

强直性脊柱炎全球市场规模研究和预测：按药物类别（NSAIDs、TNF 抑製剂、其他）、分销渠道（医院药房、零售药房、在线药房）、区域分析，2022-2029 年

Global Ankylosing Spondylitis Market Size study & Forecast, by Drug Class (NSAIDs, TNF Inhibitors and Others), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3个工作天内

价格

2021 年全球强直性脊柱炎市场价值约为 53.8 亿美元，预计在 2022-2029 年预测期内将以超过 4.6% 的健康增长率增长。

强直性脊柱炎是一种炎症性疾病，脊柱骨（椎骨）融合在一起。 这种融合会影响脊柱的柔韧性并导致不良姿势。 如果肋骨受到影响，深呼吸可能会很困难。 强直性脊柱炎的症状包括背痛、臀部疼痛、肩膀僵硬、颈部疼痛、韧带和肌腱疼痛、疲劳和盗汗。 关节炎患病率上升、强直性脊柱炎发病率上升以及主要市场参与者的战略举措是加速市场增长的主要因素。

关节炎患病率上升促进了全球强直性脊柱炎市场的增长。 例如，关节炎基金会估计——截至 2019 年，全世界有超过 5400 万成年人和大约 300,000 名儿童患有关节炎或其他类型的风湿病。 此外，强直性脊柱炎发病率的增加也推动了这一市场的增长。 例如，根据美国脊柱炎协会的数据，截至 2020 年，美国有超过 170 万成年人患有 AS。 同时，约有 320 万人患有中轴型脊柱关节炎。 此外，越来越多的骨科医院和诊断中心，以及新兴国家医疗基础设施发展的改善，也有望在预测期内为市场创造良好的增长前景。 然而，与强直性脊柱炎相关的高昂治疗费用将阻碍整个 2022-2029 年预测期内的市场增长。

强直性脊柱炎全球市场研究考虑的主要区域是亚太地区、北美、欧洲、拉丁美洲和世界其他地区。 由于强直性脊柱炎患病率上升和区域医疗基础设施的增长等因素，北美已成为市场份额的主要地区。 另一方面，由于老年人口增加和医疗基础设施发展等因素，预计亚太地区在预测期内将以最高复合年增长率增长。

这项研究的目的是揭示近年来各个细分市场和国家/地区的市场规模，并预测未来几年的市场规模。 该报告旨在捕捉被调查国家工业的定性和定量方面。

它还提供了关键方面的详细信息，例如决定市场未来增长的驱动因素和挑战。 此外，它还包含供利益相关者投资的微观市场潜在机会，以及对主要参与者的竞争格局和产品供应的深入分析。

按药物类别

非甾体抗炎药

肿瘤坏死因子抑製剂

杂项

按销售渠道

医院药房

零售商

在线药店

内容

第 1 章执行摘要

  • 市场概况
  • 2019 年至 2029 年按细分市场估算和预测全球市场
    • 强直性脊柱炎市场：按地区划分，2019-2029 年
    • 强直性脊柱炎市场（按药物类别）：2019-2029
    • 强直性脊柱炎市场：按分销渠道，2019-2029 年
  • 主要趋势
  • 调查方法介绍
  • 调查先决条件

第 2 章强直性脊柱炎全球市场定义和范围

  • 调查的目的
  • 市场定义和范围
    • 调查范围
    • 工业发展
  • 调查年份
  • 货币兑换率

第 3 章强直性脊柱炎的全球市场动态

  • 强直性脊柱炎市场影响分析 (2019-2029)
    • 市场驱动因素
      • 关节炎的患病率增加。
      • 强直性脊柱炎患病率增加
      • 主要市场参与者的战略举措
    • 市场挑战
      • 强直性脊柱炎的高昂治疗费用
    • 市场机会
      • 骨科医院和诊断中心的数量增加
      • 发展中地区的医疗保健基础设施有所增加

第 4 章强直性脊柱炎全球市场行业分析

  • 波特 5 力模型
    • 供应商的议价能力
    • 买家的议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争公司之间的敌对关係
  • 波特 5 力模型的未来方法 (2019-2029)
  • 害虫分析
    • 政治
    • 经济的
    • 社交
    • 技术
  • 投资招聘模式
  • 分析师的结论和建议
  • 顶级投资机会
  • 关键成功策略

第 5 章风险评估：COVID-19 的影响

  • 评估 COVID-19 对行业的总体影响
  • COVID-19 之前和 COVID-19 之后的市场情景

第 6 章全球强直性脊柱炎市场：按药物类别分类

  • 市场概况
  • 全球强直性脊柱炎市场：按药物类别、性能-潜力分析
  • 2019-2029 年按药物类别划分的全球强直性脊柱炎市场、估计和预测
  • 强直性脊柱炎市场细分分析
    • 非甾体抗炎药
    • 肿瘤坏死因子抑製剂
    • 其他

第 7 章：全球强直性脊柱炎市场：按分销渠道

  • 市场概况
  • 全球强直性脊柱炎市场：按分销渠道进行的性能潜力分析
  • 全球强直性脊柱炎市场：按分销渠道估算和预测 (2019-2029)
  • 强直性脊柱炎市场细分分析
    • 医院药房
    • 零售药房
    • 在线药店

第 8 章全球强直性脊柱炎市场：区域分析

  • 强直性脊柱炎市场：按地区划分的市场概况
  • 北美
    • 美国
      • 2019-2029 年按药物类别的估计和预测
      • 2019-2029 年各分销渠道的估计和预测
    • 加拿大
  • 欧洲强直性脊柱炎市场概况
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 意大利
    • 其他欧洲地区
  • 亚太地区强直性脊柱炎市场概况
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 韩国
    • 其他亚太地区
  • 拉丁美洲强直性脊柱炎市场概况
    • 巴西
    • 墨西哥
  • 世界其他地区

第 9 章衝突信息

  • 顶级市场策略
  • 公司简介
    • AbbVie Inc.
      • 主要信息
      • 概览
      • 财务信息（取决于数据可用性）
      • 产品概述
      • 近期趋势
    • Amgen, Inc,
    • Eli Lilly and Company
    • Gilead Sciences Inc
    • Janssen Pharmaceuticals
    • Merck & Co. Inc
    • Novartis AG,
    • Pfizer, Inc
    • Reliance Life Sciences Pvt. Ltd
    • UCB, Inc.,

第 10 章研究过程

  • 研究过程
    • 数据挖掘
    • 分析
    • 市场评估
    • 验证
    • 出版
  • 调查属性
  • 调查先决条件

Global Ankylosing Spondylitis Market is valued at approximately USD 5.38 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 4.6% over the forecast period 2022-2029. Ankylosing Spondylitis refers to an inflammatory disease that causes the bones in the spine (vertebrae) to fuse. This fusing affects the spine's flexibility and can result in poor posture. If ribs are affected, it can be difficult to breathe deeply. Ankylosing Spondylitis symptoms include pain in the lower back, hips, and buttocks, stiffness in the lower back, hips, and buttocks. neck pain, ligament and tendon pain, tiredness, and night sweats among others. The growing prevalence of Arthritis and rising incidences of Ankylosing Spondylitis as well as strategic initiatives from leading market players are key factors accelerating the market growth.

The rising prevalence of Arthritis is contributing to the growth of the Global Ankylosing Spondylitis Market. For instance, according to Arthritis Foundation estimates - as of 2019, globally more than 54 million adults and approximately 300,000 children are affected by arthritis or another type of rheumatic disease. Moreover, increasing incidences of Ankylosing Spondylitis are also fueling up the growth of the Market. For instance, as per Spondylitis Association of America - as of 2020 more than 1.7 million adults in the U.S. are affected by AS. Whereas, around 3.2 million have a form of axial spondyloarthritis. Also, the rising number of orthopedic hospitals and diagnostic centers and growing healthcare infrastructure in developing regions would create lucrative growth prospects for the market over the forecast period. However, the high treatment cost associated with Ankylosing Spondylitis stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Ankylosing Spondylitis Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of market share due to factors such as the rising prevalence of Ankylosing Spondylitis as well as growing healthcare infrastructure in the region. Whereas the Asia Pacific is expected to grow with the highest CAGRduring the forecast period, owing to factors such as rising geriatric individuals as well as growing healthcare infrastructure in the region.

Major market players included in this report are:

AbbVie Inc.

Amgen, Inc,

Eli Lilly and Company

Gilead Sciences Inc.

Janssen Pharmaceuticals

Merck & Co. Inc

Novartis AG,

Pfizer, Inc

Reliance Life Sciences Pvt. Ltd

UCB, Inc.,

Recent Developments in the Market:

  • In December 2021, US-based Pfizer has received FDA approval for its Tofacitinib. Tofacitinib is the first Janus kinase (JAK) inhibitor, or JAKi, that received approval for treatment of adults with active AS.

Global Ankylosing Spondylitis Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered: Drug Class, Distribution Channel, Region

Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class

NSAIDs

TNF Inhibitors

Others

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Ankylosing Spondylitis Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Ankylosing Spondylitis Market, by Drug Class, 2019-2029 (USD Billion)
    • 1.2.3. Ankylosing Spondylitis Market, by Distribution Channel, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Ankylosing Spondylitis Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Ankylosing Spondylitis Market Dynamics

  • 3.1. Ankylosing Spondylitis Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Growing prevalence of Arthritis.
      • 3.1.1.2. Growing incidences of Ankylosing Spondylitis
      • 3.1.1.3. Strategic initiatives from leading market players
    • 3.1.2. Market Challenges
      • 3.1.2.1. High treatment cost of Ankylosing Spondylitis
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growing number of orthopedic hospitals and diagnostic centers
      • 3.1.3.2. Rising healthcare infrastructure in developing regions.

Chapter 4. Global Ankylosing Spondylitis Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Investment Adoption Model
  • 4.5. Analyst Recommendation & Conclusion
  • 4.6. Top investment opportunity
  • 4.7. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Ankylosing Spondylitis Market, by Drug Class

  • 6.1. Market Snapshot
  • 6.2. Global Ankylosing Spondylitis Market by Drug Class, Performance - Potential Analysis
  • 6.3. Global Ankylosing Spondylitis Market Estimates & Forecasts by Drug Class 2019-2029 (USD Billion)
  • 6.4. Ankylosing Spondylitis Market, Sub Segment Analysis
    • 6.4.1. NSAIDs
    • 6.4.2. TNF inhibitors
    • 6.4.3. Others

Chapter 7. Global Ankylosing Spondylitis Market, by Distribution Channel

  • 7.1. Market Snapshot
  • 7.2. Global Ankylosing Spondylitis Market by Distribution Channel, Performance - Potential Analysis
  • 7.3. Global Ankylosing Spondylitis Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
  • 7.4. Ankylosing Spondylitis Market, Sub Segment Analysis
    • 7.4.1. Hospital pharmacy
    • 7.4.2. Retail pharmacy
    • 7.4.3. Online pharmacy

Chapter 8. Global Ankylosing Spondylitis Market, Regional Analysis

  • 8.1. Ankylosing Spondylitis Market, Regional Market Snapshot
  • 8.2. North America Ankylosing Spondylitis Market
    • 8.2.1. U.S. Ankylosing Spondylitis Market
      • 8.2.1.1. Drug Class breakdown estimates & forecasts, 2019-2029
      • 8.2.1.2. Distribution Channel breakdown estimates & forecasts, 2019-2029
    • 8.2.2. Canada Ankylosing Spondylitis Market
  • 8.3. Europe Ankylosing Spondylitis Market Snapshot
    • 8.3.1. U.K. Ankylosing Spondylitis Market
    • 8.3.2. Germany Ankylosing Spondylitis Market
    • 8.3.3. France Ankylosing Spondylitis Market
    • 8.3.4. Spain Ankylosing Spondylitis Market
    • 8.3.5. Italy Ankylosing Spondylitis Market
    • 8.3.6. Rest of Europe Ankylosing Spondylitis Market
  • 8.4. Asia-Pacific Ankylosing Spondylitis Market Snapshot
    • 8.4.1. China Ankylosing Spondylitis Market
    • 8.4.2. India Ankylosing Spondylitis Market
    • 8.4.3. Japan Ankylosing Spondylitis Market
    • 8.4.4. Australia Ankylosing Spondylitis Market
    • 8.4.5. South Korea Ankylosing Spondylitis Market
    • 8.4.6. Rest of Asia Pacific Ankylosing Spondylitis Market
  • 8.5. Latin America Ankylosing Spondylitis Market Snapshot
    • 8.5.1. Brazil Ankylosing Spondylitis Market
    • 8.5.2. Mexico Ankylosing Spondylitis Market
  • 8.6. Rest of The World Ankylosing Spondylitis Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. AbbVie Inc.
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Amgen, Inc,
    • 9.2.3. Eli Lilly and Company
    • 9.2.4. Gilead Sciences Inc
    • 9.2.5. Janssen Pharmaceuticals
    • 9.2.6. Merck & Co. Inc
    • 9.2.7. Novartis AG,
    • 9.2.8. Pfizer, Inc
    • 9.2.9. Reliance Life Sciences Pvt. Ltd
    • 9.2.10. UCB, Inc.,

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Ankylosing Spondylitis Market, report scope
  • TABLE 2. Global Ankylosing Spondylitis Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Ankylosing Spondylitis Market estimates & forecasts by Drug Class 2019-2029 (USD Billion)
  • TABLE 4. Global Ankylosing Spondylitis Market estimates & forecasts by Distribution Channel 2019-2029 (USD Billion)
  • TABLE 5. Global Ankylosing Spondylitis Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Ankylosing Spondylitis Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Ankylosing Spondylitis Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Ankylosing Spondylitis Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Ankylosing Spondylitis Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Ankylosing Spondylitis Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Ankylosing Spondylitis Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Ankylosing Spondylitis Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Ankylosing Spondylitis Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Ankylosing Spondylitis Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. U.S. Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. Canada Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 19. Canada Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. UK Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 22. UK Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. Germany Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 25. Germany Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. France Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 28. France Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. Italy Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 31. Italy Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Spain Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 34. Spain Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. RoE Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 37. RoE Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. China Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 40. China Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. India Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 43. India Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. Japan Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 46. Japan Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. South Korea Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 49. South Korea Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. Australia Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 52. Australia Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. Brazil Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 58. Brazil Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Mexico Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 61. Mexico Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. RoLA Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 64. RoLA Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. Row Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 67. Row Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Ankylosing Spondylitis Market
  • TABLE 70. List of primary sources, used in the study of global Ankylosing Spondylitis Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Ankylosing Spondylitis Market, research methodology
  • FIG 2. Global Ankylosing Spondylitis Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Ankylosing Spondylitis Market, key trends 2021
  • FIG 5. Global Ankylosing Spondylitis Market, growth prospects 2022-2029
  • FIG 6. Global Ankylosing Spondylitis Market, porters 5 force model
  • FIG 7. Global Ankylosing Spondylitis Market, pest analysis
  • FIG 8. Global Ankylosing Spondylitis Market, value chain analysis
  • FIG 9. Global Ankylosing Spondylitis Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Ankylosing Spondylitis Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Ankylosing Spondylitis Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Ankylosing Spondylitis Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Ankylosing Spondylitis Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Ankylosing Spondylitis Market, regional snapshot 2019 & 2029
  • FIG 15. North America Ankylosing Spondylitis Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Ankylosing Spondylitis Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Ankylosing Spondylitis Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Ankylosing Spondylitis Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Ankylosing Spondylitis Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable